These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 6400094)

  • 1. Bacterial urinary assay in monitoring exposure to mutagens and carcinogens.
    Vainio H; Sorsa M; Falck K
    IARC Sci Publ; 1984; (59):247-58. PubMed ID: 6400094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological monitoring of occupational exposure to mutagenic chemicals in the rubber industry. Use of the bacterial urinary mutagenicity assay.
    Falck K
    Scand J Work Environ Health; 1983; 9 Suppl 2():39-42. PubMed ID: 6356339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of low levels of urinary mutagen excretion by chemotherapy workers which was not related to occupational drug exposures.
    Everson RB; Ratcliffe JM; Flack PM; Hoffman DM; Watanabe AS
    Cancer Res; 1985 Dec; 45(12 Pt 1):6487-97. PubMed ID: 4063994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limitations of urinary mutagen assays for monitoring occupational exposure to antineoplastic drugs.
    Tuffnell PG; Gannon MT; Dong A; DeBoer G; Erlichman C
    Am J Hosp Pharm; 1986 Feb; 43(2):344-8. PubMed ID: 3513557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutagenicity studies in a tyre plant: in-vitro activity of urine concentrates and rubber chemicals.
    Crebelli R; Falcone E; Aquilina G; Carere A; Paoletti A; Fabri G
    IARC Sci Publ; 1984; (59):289-95. PubMed ID: 6400096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The AMES test in environmental and occupational medicine].
    Clonfero E; Saia B
    Med Lav; 1990; 81(1):3-10. PubMed ID: 2199806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exposure to carcinogenic chemicals and smoking increases urinary excretion of mutagens in humans.
    Dolara P; Mazzoli S; Rosi D; Buiatti E; Baccetti S; Turchi A; Vannucci V
    J Toxicol Environ Health; 1981; 8(1-2):95-103. PubMed ID: 7328717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salmonella/human S9 mutagenicity test: a collaborative study with 58 compounds.
    Hakura A; Shimada H; Nakajima M; Sui H; Kitamoto S; Suzuki S; Satoh T
    Mutagenesis; 2005 May; 20(3):217-28. PubMed ID: 15843387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutagenic activity of overnight urine from healthy non-smoking subjects.
    Pavanello S; Lupi S; Pulliero A; Gregorio P; Saia BO; Clonfero E
    Environ Mol Mutagen; 2007 Mar; 48(2):143-50. PubMed ID: 17295305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bacterial urinary mutagenicity test for monitoring of exposure to genotoxic compounds: a review.
    Cerná M; Pastorková A
    Cent Eur J Public Health; 2002 Sep; 10(3):124-9. PubMed ID: 12298345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The correlation between the excretion of thioethers and their mutagenic activity in urine in workers of different occupational groups].
    Kouros BM; Böttger A; Dehnen W
    Zentralbl Hyg Umweltmed; 1989 Nov; 189(2):125-34. PubMed ID: 2604844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basic concepts of monitoring human exposure.
    Lauwerys R
    IARC Sci Publ; 1984; (59):31-6. PubMed ID: 6545283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of bacterial assay system for monitoring genotoxic complex mixtures in the occupational setting.
    Ong T; Stewart JD; Whong WZ
    IARC Sci Publ; 1990; (104):101-6. PubMed ID: 2228106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exposure to mutagenic aromatic hydrocarbons of workers creosoting wood.
    Bos RP; Jongeneelen FJ; Theuws JL; Henderson PT
    IARC Sci Publ; 1984; (59):279-88. PubMed ID: 6400095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SOS chromotest results in a broader context: empirical relationships between genotoxic potency, mutagenic potency, and carcinogenic potency.
    White PA; Rasmussen JB
    Environ Mol Mutagen; 1996; 27(4):270-305. PubMed ID: 8665872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of handling injectable antineoplastic agents.
    Anderson RW; Puckett WH; Dana WJ; Nguyen TV; Theiss JC; Matney TS
    Am J Hosp Pharm; 1982 Nov; 39(11):1881-7. PubMed ID: 6756133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-walled carbon nanotubes: Lack of mutagenic activity in the bacterial reverse mutation assay.
    Di Sotto A; Chiaretti M; Carru GA; Bellucci S; Mazzanti G
    Toxicol Lett; 2009 Feb; 184(3):192-7. PubMed ID: 19063954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1,3-butadiene: cancer, mutations, and adducts. Part III: In vivo mutation of the endogenous hprt genes of mice and rats by 1,3-butadiene and its metabolites.
    Walker VE; Meng Q
    Res Rep Health Eff Inst; 2000 Mar; (92):89-139; discussion 141-9. PubMed ID: 10925840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The proportions of mutagens among chemicals in commerce.
    Zeiger E; Margolin BH
    Regul Toxicol Pharmacol; 2000 Oct; 32(2):219-25. PubMed ID: 11067778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutagenic activity of chemicals previously tested for carcinogenicity in the National Cancer Institute bioassay program.
    Dunkel VC; Simmon VF
    IARC Sci Publ; 1980; (27):283-301. PubMed ID: 7002779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.